Table S5.
Annual rates of adverse events associated with PsO, PsA, and AS treatment
| Treatment option | PsO
|
PsA
|
AS
|
||||
|---|---|---|---|---|---|---|---|
| Serious infection | NMSC | Malignancies other than NMSC | Serious infection | NMSC | Serious infection | NMSC | |
| Secukinumab 150 mg | – | – | – | 1.4%6 | 2.1%6 | 0.9%7 | 0.9%7 |
| Secukinumab 300 mg | 1.4%8 | 0.4%8 | 0.3%8 | 2.8%6 | 0.0%6 | – | – |
| Adalimumab 40 mg | 5.2%a | 0.9%a | 0.6%a | 2.8%9 | 0.1%9 | 1.4%9 | 0.5%9 |
| Certolizumab 200 mg | – | – | – | 3.1%10 | 0.0%10 | 3.9%11 | 0.0%11 |
| Etanercept 50 mg | 5.1%a | 3.5%a | 0.0%a | 1.7%12 | 0.6%12 | 0.0%13 | 0.0%13 |
| Etanercept biosimilar | 5.1%b | 3.5%b | 0.0%b | 1.7%b | 0.6%b | 0.0%b | 0.0%b |
| Golimumab 50 mg | – | – | – | 1.4%14 | 0.0%14 | 0.4%15 | 0.0%15 |
| Ixekizumab | 0.02%a | 0.0%a | 0.0%a | – | – | – | – |
| Ustekinumab 45 mg | 0.0%a | 0.5%a | 0.6%a | 0.8%16 | 0.4%16 | – | – |
| Infliximab | 5.5%a | 0.4%a | 7.7%a | 1.9%17 | 1.9%17 | 2.1%18 | 0%18 |
| Infliximab bios | 5.5%b | 0.4%b | 7.7%b | 1.9%b | 1.9%b | 2.1%b | 0%b |
| Apremilast 30 mg | – | – | – | 2.6%19 | 1.3%19 | – | – |
Notes: Only serious adverse events due to malignancies and severe infections requiring hospitalization were included in the analysis. Severe infections included sepsis, tuberculosis, skin and soft tissue infections, bone and joint infections, pneumonia, and urinary tract infections.
a
Data obtained from product label.
b
Assumed same as corresponding branded drug. “–” Indicates a treatment (at a given dose strength) is not considered for the indication mentioned.
Abbreviations: AS, ankylosing spondylitis; NMSC, non-melanoma skin cancer; PsA, psoriatic arthritis; PsO, psoriasis.